Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now later-stage tilt small index

Early Alzheimer's Disease: later-stage trial registry

2 of 8 indexed Early Alzheimer's Disease trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #2,176 of 28,707 conditions by registered trial count.

Jump to open trials → Trial finder

8 US clinical trials · 2 currently recruiting · #2,176 of 28,707 conditions by registered trial count

Early Alzheimer's Disease: 8 US clinical trials tracked, 2 recruiting.

Early Alzheimer's Disease is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 6 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Alzheon, running 2 of these trials.

Enrollment posture brief

Registry condition early-alzheimers-disease

OPEN 2 | RECR 25% | LATE 6 | EARLY 2 | RANK #2176 | SPON 2

Volume-matched condition peers

Nearest open-share peer: Abdominal Pain (25% recruiting · 20 trials)

Activity, Motor75%Achalasia50%Abdominal Cancer25%Acne Scars - Mixed Atrophic 25%Early Alzheimer's Diseas (th…25%
Open-enrollment share among volume-matched conditions near Early Alzheimer's Disease

Early Alzheimer's Disease lists 2 open slots (25% of 8 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Early Alzheimer's Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Early Alzheimer's Disease is recruiting below its size-band peers.

    2 of 8 indexed trials (25%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Early Alzheimer's Disease research.

    Alzheon accounts for 2 of 8 trials (25%). 6 distinct sponsors appear on at least one study for this condition label.

  3. Typical Early Alzheimer's Disease enrolment sits around 760 participants.

    Median target enrolment is 760 among the 8 trials that report a genuine target (sentinel values excluded). 0 of those (0%) plan for fewer than 100 participants.

  4. Early Alzheimer's Disease research is mostly interventional.

    8 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 22Phase 36

Phase Distribution

PhaseTrial count
Phase 2 2
Phase 3 6

Top Sponsors

Alzheon 2 trials
Novo Nordisk A/S 2 trials
Cognition Therapeutics 1 trials
Annovis Bio 1 trials
Eisai 1 trials
Merck Sharp & Dohme 1 trials

Named interventions

Most-linked intervention names on Early Alzheimer's Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
4 trials
Experimental: ALZ-801 Drug
2 trials
Placebo (semaglutide) Drug
2 trials
Semagludtide Drug
1 trials
CT1812 Drug
1 trials
Lecanemab SC Drug
1 trials
Lecanemab IV Drug
1 trials
buntanetap/posiphen Drug
1 trials

US sites by state

Facility locations filed on Early Alzheimer's Disease trials. A trial with sites in several states counts in each.

California 8 trials
Arizona 7 trials
Florida 5 trials
Connecticut 5 trials
Colorado 4 trials
New York 1 trials
New Jersey 1 trials
Massachusetts 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Early Alzheimer's Disease page

8 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 2 Early Alzheimer's Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Alzheon sponsors the most Early Alzheimer's Disease trials on record, review their full trial history before evaluating a specific study. See Alzheon's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Early Alzheimer's Disease condition card totals 8 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.